Breaking News Instant updates and real-time market news.

GILD

Gilead

$63.93

0.47 (0.74%)

14:41
08/21/19
08/21
14:41
08/21/19
14:41

Gilead says submitted petitions to USPTO requesting review of HHS patents

Gilead announced that it has submitted petitions to the U.S. Patent and Trademark Office requesting an inter partes review of patents granted to the U.S. Department of Health and Human Services for HIV pre-exposure prophylaxis and post-exposure prophylaxis. An inter partes review re-examines the claims in a patent to determine whether they are valid. The company stated: "We strongly believe that the patents granted to HHS since 2015 for PrEP and PEP are not valid. Published materials clearly show that well before HHS claims to have invented the concepts of PrEP and PEP in 2006, others had conceived of using an antiretroviral therapy, including Truvada, for both forms of prophylaxis. For example, guidelines published in 2004 recommended administering combination antiretrovirals - including Truvada - to certain categories of 'high risk' individuals before an HIV exposure, while the Center for Disease Control and Prevention's own 2005 guidelines recommended Truvada for prophylaxis immediately after exposure. The ongoing dialogue about these patents is a distraction from the important work being done by Gilead and its many community partners to reduce barriers to PrEP. Resolving the patent issues will refocus the public dialogue about PrEP on what matters most: the real-world obstacles that prevent people at risk for HIV from accessing effective prevention. Those with the greatest need for PrEP face significant social and structural barriers, such as limited access to affordable healthcare, low awareness of PrEP, stigma, discrimination, and insurance benefit design that places a significant cost-sharing burden on patients. Gilead remains committed to increasing access to PrEP for everyone in need and we will continue to invest in a wide range of programs to help accelerate access and awareness."

  • 09

    Sep

GILD Gilead
$63.93

0.47 (0.74%)

07/29/19
07/29/19
UPGRADE
Target $91

Top Pick
Gilead upgraded to Top Pick from Outperform at RBC Capital
As previously reported, RBC Capital analyst Brian Abrahams upgraded Gilead Sciences to Top Pick from Outperform with a price target of $91. The analyst says the stock represents a "compelling opportunity" with limited downside risks as the company's HIV franchise generates a "steady" annual revenue of about $16B per year over the medium term given the "very strong" uptake of its Biktarvy. according to prescription data. Abrahams adds that in spite of Gilead's earnings stabilization visibility, the stock remains "significantly discounted" at 10-times earnings relative to peers' 12-times multiple.
07/29/19
RBCM
07/29/19
NO CHANGE
Target $171
RBCM
Sector Perform
Galapagos price target raised to $171 from $132 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Galapagos (GLPG) to $171, saying the company is in a "comfortable position" after its "lucrative" Gilead (GILD) deal and the elevation of Filgotinib to commercial status possibly coming next year. The analyst cites the FDA's greater permissiveness on filing and the company's latest comments on Filgotinib safety, though he also intends to monitor the "competitive dynamics" to gauge the program's long-term potential.
07/29/19
07/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ericsson (ERIC) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Alexander Duval citing his view that its fundamentals are solid in Networks, Digital Services and Managed Services but the stock has pulled back by about 5% relative to the others in EU Tech since the company's Q2 report on July 17. 2. AB InBev (BUD) upgraded to Buy from Neutral at BofA/Merrill with analyst Fernando Ferreira saying the cycle of downward earnings revisions is coming to an end. 3. Volaris (VLRS) upgraded to Overweight from Equal Weight at Barclays with analyst Pablo Monsivais saying he sees share upside given the company's "simple model" that drives the lowest possible costs. 4. NXP Semiconductors (NXPI) upgraded to Outperform from In Line at Evercore ISI. 5. Gilead (GILD) upgraded to Top Pick from Outperform at RBC Capital with analyst Brian Abrahams saying the stock represents a "compelling opportunity" with limited downside risks as the company's HIV franchise generates a "steady" annual revenue of about $16B per year over the medium term given the "very strong" uptake of its Biktarvy, according to prescription data. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/19
PIPR
07/30/19
NO CHANGE
Target $75
PIPR
Neutral
Gilead's Biktarvy impressive but near-term acceleration needed, says Piper
Piper Jaffray analyst Tyler Van Buren keeps his Neutral rating and $75 price target on Gilead after its "good" Q2 results and raised outlook for FY19 product sales. The analyst notes that the launch of Bikvarty continues to be "impressive", though its performance offsets declines in other antiviral products. Van Buren adds that Gilead's revenue stability is "comforting", but he prefers to see some near-term acceleration, which he contends is possible with filgotinib expected to be submitted by year-end.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
09/19/19
09/19
15:17
09/19/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
09/19/19
09/19
15:16
09/19/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRC

California Resources

$12.03

-1.985 (-14.16%)

15:15
09/19/19
09/19
15:15
09/19/19
15:15
Hot Stocks
California Resources down 26% to $10.34 in late day trading »

At time of writing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRC

California Resources

$12.03

-1.985 (-14.16%)

15:15
09/19/19
09/19
15:15
09/19/19
15:15
Options
California Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$7.30

0.4 (5.80%)

15:05
09/19/19
09/19
15:05
09/19/19
15:05
Options
Rite Aid call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SQ

Square

$58.77

-0.94 (-1.57%)

, LC

LendingClub

$14.60

-0.105 (-0.71%)

15:00
09/19/19
09/19
15:00
09/19/19
15:00
Periodicals
Fintech firm Stripe gets $35B valuation with latest funding round, WSJ reports »

Fintech company Stripe…

SQ

Square

$58.77

-0.94 (-1.57%)

LC

LendingClub

$14.60

-0.105 (-0.71%)

FISV

Fiserv

$105.34

1.14 (1.09%)

PYPL

PayPal

$106.02

0.42 (0.40%)

FNTE

FinTech Acquisition

$0.00

(0.00%)

BABA

Alibaba

$181.85

1.81 (1.01%)

LX

LexinFintech

$11.40

0.15 (1.33%)

ADYYF

Adyen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 27

    Oct

  • 06

    Nov

GDOT

Green Dot

$27.48

0.19 (0.70%)

14:55
09/19/19
09/19
14:55
09/19/19
14:55
Conference/Events
Green Dot participates in a conference call with SunTrust »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

STXS

Stereotaxis

$4.07

-0.27 (-6.22%)

14:52
09/19/19
09/19
14:52
09/19/19
14:52
Syndicate
Breaking Syndicate news story on Stereotaxis »

Stereotaxis files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.77

-0.52 (-3.19%)

14:43
09/19/19
09/19
14:43
09/19/19
14:43
Periodicals
Macy's to offer free same-day delivery for a limited time, Retail Dive reports »

Macy's has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TTEC

TTEC Holdings

$49.79

0.24 (0.48%)

14:41
09/19/19
09/19
14:41
09/19/19
14:41
Initiation
TTEC Holdings initiated  »

TTEC Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

IRBT

iRobot

$61.87

-0.58 (-0.93%)

14:35
09/19/19
09/19
14:35
09/19/19
14:35
Options
iRobot put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CNNE

Cannae Holdings

$26.72

-0.02 (-0.07%)

14:32
09/19/19
09/19
14:32
09/19/19
14:32
Hot Stocks
Cannae Holdings announces three-year, 5M share repurchase program »

Cannae Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 13

    Nov

TSL

Trina Solar

$0.00

(0.00%)

, CSIQ

Canadian Solar

$22.24

0.56 (2.58%)

14:28
09/19/19
09/19
14:28
09/19/19
14:28
Periodicals
Solar and wind power 'so cheap they're outgrowing subsidies,' Bloomberg says »

According to…

TSL

Trina Solar

$0.00

(0.00%)

CSIQ

Canadian Solar

$22.24

0.56 (2.58%)

SPWR

SunPower

$15.20

0.775 (5.37%)

FSLR

First Solar

$67.32

1.55 (2.36%)

JASO

JA Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

SUNEQ

SunEdison

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
09/19/19
09/19
14:20
09/19/19
14:20
General news
Treasury Action: Treasuries are holding modest gains »

Treasury Action:…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/19/19
09/19
14:17
09/19/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/19/19
09/19
14:16
09/19/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGM

LogMeln

$68.03

-0.63 (-0.92%)

14:11
09/19/19
09/19
14:11
09/19/19
14:11
Periodicals
Breaking Periodicals news story on LogMeln »

LogMeln turns positive,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$42.86

-0.06 (-0.14%)

, VAR

Varian Medical

$115.91

-1.54 (-1.31%)

14:11
09/19/19
09/19
14:11
09/19/19
14:11
Hot Stocks
Boston Scientific required to divest certain assets to Varian regarding BTG buy »

Medical device company…

BSX

Boston Scientific

$42.86

-0.06 (-0.14%)

VAR

Varian Medical

$115.91

-1.54 (-1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 23

    Oct

  • 13

    Nov

LOGM

LogMeln

$68.03

-0.63 (-0.92%)

14:10
09/19/19
09/19
14:10
09/19/19
14:10
Periodicals
Dealreporter says LogMeln having informal talks on selling parts, Bloomberg says »

Bloomberg cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$9.47

0.085 (0.91%)

14:06
09/19/19
09/19
14:06
09/19/19
14:06
Periodicals
Nelson Peltz says GE CEO Larry Culp is 'fantastic,' Reuters reports »

Trian Partners'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

HIIQ

Health Insurance Innovations

$22.37

1.59 (7.65%)

14:05
09/19/19
09/19
14:05
09/19/19
14:05
Options
Health Insurance Innovations call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 02

    Oct

STX

Seagate

$52.92

-3.82 (-6.73%)

13:59
09/19/19
09/19
13:59
09/19/19
13:59
Recommendations
Seagate analyst commentary  »

Seagate price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SPY

SPDR S&P 500 ETF Trust

$301.58

0.48 (0.16%)

, SPX

S&P 500

$0.00

(0.00%)

13:51
09/19/19
09/19
13:51
09/19/19
13:51
General news
Global Times' Xijin says China 'not as anxious to reach a deal' as U.S. thought »

Hu Xijin, editor-in-chief…

SPY

SPDR S&P 500 ETF Trust

$301.58

0.48 (0.16%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFL

Aflac

$52.71

0.11 (0.21%)

13:48
09/19/19
09/19
13:48
09/19/19
13:48
Conference/Events
Aflac to host analyst briefing »

Financial Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

ZYNE

Zynerba

$8.19

-0.65 (-7.35%)

, GWPH

GW Pharmaceuticals

$134.90

-0.73 (-0.54%)

13:47
09/19/19
09/19
13:47
09/19/19
13:47
Recommendations
Zynerba, GW Pharmaceuticals analyst commentary  »

Zynerba selloff on…

ZYNE

Zynerba

$8.19

-0.65 (-7.35%)

GWPH

GW Pharmaceuticals

$134.90

-0.73 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.